Navigation Links
Letter to Z Trim Shareholders
Date:4/16/2008


MUNDELIEN, Ill., April 16 /PRNewswire-FirstCall/

To: Z Trim Shareholders

RE: Investor Update: Q1/08

Dear Fellow Shareholders:

In keeping with our pledge to increase transparency and improve the effectiveness of communication with our investor community, we are initiating a series of periodic updates to help keep you informed about our Company's progress. The Board, management and staff of Z Trim Holdings, Inc. (Z Trim) (Amex: ZTM) deeply appreciate your ongoing faith and support and want you to know that we are working hard to rebuild this enterprise for sustainable, long term growth.

I use the term "rebuild" to convey the reality of our present undertaking. While the leadership team believes implicitly in the extraordinary potential of this Company, both to deliver strong returns to our shareholders and to improve the health and welfare of millions of consumers, the fact remains that significant work will be necessary in order to realize it. With this in mind, I will spend a little extra space in this inaugural communication to address some challenges that we have overcome and some that we are still working on. Future editions will follow a more traditional format of concise updates on key topics with less introductory commentary.

We take great pride in the progress we have made since our annual shareholder meeting in December 2007, including:
-- Resolution of Amex Deficiency Status -- We stated that priority number

one was to resolve Z Trim's regulatory compliance status with the

American Stock Exchange and in February, were pleased to announce that

Amex had found the Company to be fully compliant with all listing

standards, thereby eliminating
'/>"/>

SOURCE Z Trim
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Breckenridge Pharmaceutical Signs Letter of Intent for Long Term Agreement With Orit Laboratories (West Caldwell, NJ)
2. Open Letter to Presidential Candidates on State Health Care Reform
3. GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting
4. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
5. MassMutual Offers Free Letter of Intent Template to People with Disabilities and Their Families, Caregivers
6. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
7. Open Letter to Speaker Pelosi on Approval of Mental Health Parity
8. Highlands Acquisition Corp. Receives Non-Compliance Letter From Amex
9. AHCA, Alliance Praise Bipartisan Johnson, Collins Letter Urging Rejection of Bush Medicare Cuts
10. Texas Health Care Association Asks Texas Congressional Delegation to Sign Letter Urging House Budget Committee to Rescind Bush Medicare Cuts
11. Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...e disgraced stem-cell scientist has been suspended...006, along with six other researchers. This measur... regard to their research work.// The seven profes...ng at the university or conducting research. They ...
...cy across the world is increasing, and it is estim...in their 30s will live to see their 100th birthday...n of centenarians is expected to soar from the pre...y 2074 in Britain, according to the Daily Mail. ...
...ernment has been called upon to provide better inc...e pharmacies. More people are being turned away as...gram, for which the Government has been faulted. /...r has revealed that the program has the involvemen...
... offered by generic drug makers may well eat into ...o company sources. The Cox-2 painkiller of the org...this.// The company is also embroiled in a tax rel...sales of the company for the year rose by13% at ?2...
Other Medicine News:
(Date:9/4/2008)...e/ -- Cytopia Limited (ASX:,CYT) today announced t...,study of CYT997, the company,s novel vascular-dis...essive form of brain cancer known as glioblastoma,...first Phase II efficacy study in highly,vascular, ...cond in its,suite of Phase II studies designed to ...
(Date:9/4/2008)...resented at ESC Congress-, PHILADELPHIA, Sept. 4 ...tudy, the GISSI Heart Failure (GISSI-HF) study, sh...reduced all cause mortality and hospital,admission...nic heart,failure. These findings are published in...re presented at the European Cardiovascular Societ...
(Date:9/4/2008)...wire/ -- Axentis Pharma AG has,initiated a clinica...ility,of a new therapeutic formulation for the tre...rosis patients. The new formulation allows an,esta... to the site of,infection. The forthcoming trial w...s of the new drug. Initial results are expected in...
(Date:9/4/2008)...h Two Abstracts Accepted for Presentation, and...IDGEWATER, N.J., Sept. 4 /- Aegerion ...company focused on the treatment of,cardiovascular...tment of,Peter L. Garrambone, Jr. to the Company,s...ncludes more than 50 pharmaceutical,transactions e...
Breaking Medicine Technology:Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Wisconsin researchers describe how digits grow 2471 1Wisconsin researchers describe how digits grow 2471 2Wisconsin researchers describe how digits grow 2471 3BioAnalytics Group CEO Senior Scientist to Present at Tucson Symposium March 12 13 3875 1BioAnalytics Group CEO Senior Scientist to Present at Tucson Symposium March 12 13 3875 2Penn research offers road map to safer pain control cost savings during colonoscopies 14067 1Penn research offers road map to safer pain control cost savings during colonoscopies 14067 2Policing cells demand ID to tell friend from foe say University of Pennsylvania cell engineers 2467 1Policing cells demand ID to tell friend from foe say University of Pennsylvania cell engineers 2467 2
...INESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC.,(NASD...oncology and,acute care, today announced that a ra...e 3 trial of Aquavan(R) (fospropofol,disodium) Inj...scopy successfully met its primary endpoint of sed...Among patients who,received an initial bolus dose ...
...eased Enzyme Levels in Two Most Common Mutations, ...cus,Therapeutics, a biopharmaceutical company deve...ological chaperones for the,treatment of a range o...will present the results of preclinical studies of...ucher disease at,the of Medical Genetics (ACMG) an...
Other Medicine Technology:MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 2MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 3MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 4MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 5MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 6Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
Tank Blotting System. Designed for Western, Northern, or Southern Blotting. Transfer up to three gels with dimensions as large as 15cm x 21.5cm. Includes and internal cooling base for temperature
... proven electrophoretic transfer apparatus incorpo...ltimate in field uniformity. Its design allows for... when coupled with a low voltage power source such...ts/cm. The result is exceptionally rapid and exact...
...lot cell, a component of Bio-Rad's modular mini el...resis Systems), provides rapid, high-quality blott...ransfers two 7.5 x 10 cm gels in just 1 hour. Cool... absorbs heat generated during transfers. The Mini...
Includes PowerPac 200 power supply. Flexibility for a Range of Parameters. Quantitative Transfers. Native Enzyme, High Intensity, or Overnight Transfers. Faster, Higher-Efficiency Transfers via Pl
Medicine Products: